Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of IBI-10090 for Inflammation after Cataract Surgery
NCT01214174Phase 2Terminated
- Sponsor
- Icon Bioscience, Inc.
- Start
- Oct 2010
- Primary completion
- May 2012
- Modality
- Polymer-based Nanoparticles, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of IBI-10090 in ocular inflammation (3 arms), sponsored by Icon Bioscience, Inc. Primary endpoint: Proportion of Patients With Anterior Chamber Cell Clearing at Day 8 Post-Treatment. Started Oct 2010; status: terminated.
02
Drugs
IBI-10090
03
Conditions
ocular inflammation
Beyond the preview
Go deeper on NCT01214174.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01214174.